Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02984410
Other study ID # EORTC-1420-HNCG-ROG
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 27, 2017
Est. completion date September 2029

Study information

Verified date February 2023
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact EORTC HQ
Phone +32 2 774 16 11
Email eortc@eortc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured. Treatment of early stage OPSCC can be successfully achieved with primary surgery including neck dissection, as indicated, or with definitive radiotherapy. The current standard treatment for OPSCC is therefore based on either surgery and/or radiotherapy, both associated with comparable, high tumor control rates but with different side effects profiles and technical constraints. In order to decrease the potential morbidity of surgery, transoral approaches have been developed within the last decades, including transoral robotic surgery (TORS), transoral laser microsurgery (TLM) or conventional transoral techniques. On the other hand, patients with head and neck cancer treated with IMRT experienced significant improvements in cause specific survival (CSS) compared with patients treated with non-IMRT techniques thus suggesting that IMRT may be beneficial in terms of patient's outcomes and toxicity profile. It is as yet unclear however, which one of the new techniques is superior to the other in terms of function preservation. Given that the functional outcome of most importance is swallowing function, the preservation of swallowing is thus of major importance. The main objective of the study is to assess and compare the patient-reported swallowing function over the first year after randomization to either IMRT or TOS among patients with early stage OPSCC, SGSCC, and HPSCC.


Description:

Eligible patients will be randomized 1 to 1 to surgery (Arm 1) or radiotherapy (Arm 2). ARM 1: Surgery Trans-oral surgery (any trans-oral approach such as trans-oral laser microsurgery conventional trans-oral surgery or trans-oral robotic surgery) will be applied to all patients in this arm. A surgical margin is defined to be clear (R0), if found to be >/=3mm in the final specimen (except deep margin for tonsillar resection, that is either R1 or R0), is defined to be close, if 1-<3mm, and considered to be involved (R1), if <1mm in the final specimen. Clearly defined marginal biopsies are required for each TOS-technique. Trans-oral re-resections are required in case of R1 or close-margin to convert the patient to an R0-status.Postoperative RT or chemo-RT will be given within 5-6 weeks of surgery in case of positive. ARM 2: Radiotherapy Intensity modulated radiation therapy (IMRT) with Simultaneous integrated boost (SIB) will be applied to all patients in this arm. PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 112
Est. completion date September 2029
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: - OPSCC in one of the following sub-sites: base of tongue, lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus, vallecula or SGSCC in one or more of the following sub-sites: epiglottis, aryepiglottic fold, false cord or HPSCC in one or more of the following subsites: Lateral and medial wall of piriform sinus (sub-sites are defined as lateral (lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus, lateral piriform sinus) vs. central lesions (base of tongue, vallecula, all supraglottic sites, medial wall of piriform sinus)) - TNM stage I-III (7th AJCC classification): T1 or T2, N0 or T1 or T2, N1 with one single neck node = 3cm without radiographic signs of extracapsular extension (ECE), M0; - TNM stage I for HPSCC: T1, N0, M0. ; - Within 2 weeks before randomization, assessment by a Multi-Disciplinary Team (MDT) composed of at least a head and neck/ENT surgeon, oncologist, radiologist, radiotherapist, and pathologist of the treatment naïve patient and suitable for either TOS or IMRT based on: - CT with contrast and/or MRI done within 4 weeks prior to randomization Note: Repeat contrast enhanced CT and/or MRI or US 1 week or less prior to randomization in case of suspicious nodes <1cm on initial scan if per local practice - Pan-endoscopy with assessment of trans-oral exposure for resection. - peri-nodal infiltration either via CT-scan or MRI. - Age 18 and older; Age 18 to 70 for SGSCC - ECOG Performance status = 2; - Availability of biological material for HPV/p16 testing for OPSCCs - Study information and Informed consent discussed by the surgeon and radio-oncologist and signed by the patient. - Within 2 weeks prior randomization: - Baseline MDADI score available; - Adequate bone marrow function as demonstrated by neutrophils count > 1,5 109 /L , platelets count > 75 109 /L, WBC= 3.0 109 /L; - Prothrombin time (PT) with an international normalized ratio (INR) = 1.2 - Partial thromboplastin time (PTT) = 1.2 times ULN - Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test no more than 72 hours prior to randomization. - Patients of childbearing / reproductive potential should agree to use adequate birth control measures for 3 months, especially if they will undergo any radiotherapy treatment at any time during the study. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Main Exclusion Criteria: - Any previous anti-cancer therapy for HNSCC (surgery, chemo-, or radiotherapy or molecular targeted therapy); - Any active malignancy (other than non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer) within the last 5 years with ongoing systemic treatment - Cancer in contact with the internal and/or common carotid artery - Extension of OPSCC across the midline of the base-of-tongue - Arytenoid involvement in case of SGSCC - Infiltration of apex for piriform sinus in case of HPSCC - Cancer originating from the soft palate or posterior pharyngeal wall - Requirement of a reconstruction with a free or regional flap (i.e. involvement of >50% of the soft palate) - Pre-existing dysphagia not related to the oropharyngeal cancer or diagnostic biopsies - Any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Intensity-Modulated Radiation Therapy (IMRT)
IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
Procedure:
Trans Oral Surgery (TOS)
TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection

Locations

Country Name City State
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium Institut Jules Bordet-Hopital Universitaire ULB Brussels
Belgium U.Z. Leuven - Campus Gasthuisberg Leuven
Belgium CHU-UCL Namur - CHU Mont Godinne Namur Yvoir
France Hopitaux Universitaires de Strasbourg - Hautepierre Strasbourg
Germany Universitaetklinikum Halle - Martin Luther Universitaet Halle
Germany Universitaets Krankenhaus Eppendorf - UKE - University Cancer Center Hamburg
Germany Universitaetsklinikum Jena Jena
Germany Universitaetsklinikum Koeln Koeln
Germany Staedtisches Klinikum Leipzig - Klinikum St Georg Leipzig
Germany Universitaetsklinikum Leipzig Leipzig
Germany Klinikum Rechts der isar Der Technische Universitaet Muenchen Muenchen
Germany Universitaetsklinikum Tuebingen- Crona Kliniken Tübingen
Germany Universitaetsklinikum Ulm-Michelsberg-HNO Ulm
Italy Istituto Clinico Humanitas Milan
Italy Istituto Europeo di Oncologia Milan
Poland The Great Poland Cancer Centre Poznan
Spain Hospital Universitario Donostia Barcelona
Spain Hospital Universitario Ramon y Cajal Madrid
Spain Hospital Universitario Central De Asturias Oviedo
Switzerland Universitaetsspital Basel Basel
Switzerland Inselspital Bern
Switzerland Centre Hospitalier Universitaire Vaudois - Lausanne Lausanne
Switzerland UniversitaetsSpital Zurich - Klinik fur Ohren, Hals und Gesichtschirurgie Zürich
United Kingdom University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre Bristol
United Kingdom Cambridge University Hospital NHS - Addenbrookes Hospital Cambridge
United Kingdom Cardiff and Vale University Health Board - University Hospital of Wales Cardiff
United Kingdom Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital Cottingham
United Kingdom Aintree University Hospital NHS Trust Liverpool
United Kingdom Guy's and St Thomas' NHS Foundation trust - Guy s and St Thomas' NHS - Guy's Hospital London
United Kingdom Imperial College Healthcare NHS Trust - Charing Cross Hospital London
United Kingdom South Tees Hospitals NHS Foundation Trust - The James Cook University Hospital Middlesbrough

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Poland,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the MD Anderson Dysphagia Inventory (MDADI) score at 4.5 and 12 months after randomization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03656133 - Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers N/A
Terminated NCT02225496 - Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Phase 2
Withdrawn NCT01767961 - Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer N/A
Completed NCT01695122 - Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT01435252 - A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Phase 2
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Withdrawn NCT00951470 - Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema N/A
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT01342978 - Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time N/A
Completed NCT00964977 - Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Phase 3
Recruiting NCT05363709 - BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients Phase 2
Completed NCT02280811 - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Phase 2
Active, not recruiting NCT03777384 - EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
Active, not recruiting NCT03729518 - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck N/A
Recruiting NCT06121102 - Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain N/A
Recruiting NCT02960724 - uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Phase 2
Completed NCT02934724 - Impact of HPV Vaccine On The Prevalence Of HPV In Norway
Withdrawn NCT00928161 - Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Terminated NCT03555721 - CytID Analysis of Oral Lesions